Are anticoagulants still indicated in pulmonary arterial hypertension?

Keyphrases

• Anticoagulants 100%
• Anticoagulation Management 11%
• Bleeding Risk 11%
• Chronic Anticoagulation 22%
• Clinical Trials 11%
• Direct Oral Anticoagulants 22%
• Disease Mechanisms 22%
• Dominant Disease 11%
• Drug-induced Pulmonary Hypertension 11%
• Effects on Survival 11%
• Exercise Tolerance 11%
• Fatal Infection 11%
• In Situ Thrombosis 11%
• Indirect Evidence 11%
• Inflammation 11%
• Intimal Proliferation 11%
• Intraluminal Thrombosis 11%
• Mechanistic Studies 11%
• Medial Hypertrophy 11%
• Mitochondrial Dysfunction 11%
• Oral Anticoagulation 11%
• Over 40 11%
• Overall Survival 11%
• Pathological Changes 11%
• Pragmatic Approach 11%
• Prospective Randomized Trial 11%
• Pulmonary Arterial Hypertension 100%
• Pulmonary Hypertension 11%
• Pulmonary Vasodilation 11%
• Pulmonary Vasodilators 22%
• Specific Treatment 11%
• Survival Benefit 11%
• Thrombotic Lesion 22%
• Uncommon Diseases 11%
• Underlying Disease 11%
• Vascular Remodeling 11%
• Vasoconstriction 11%
• Vitamin K Antagonists 11%
• Warfarin 22%
• Working Diagnosis 11%

Medicine and Dentistry

• Anticoagulant 100%
• Anticoagulation 36%
• Artery Intima Proliferation 9%
• Clinical Trial 9%
• Direct Oral Anticoagulant 18%
• Diseases 36%
• Exercise Tolerance 9%
• Mitochondrial Disorder 9%
• Observational Study 9%
• Overall Survival 9%
• Peripheral Vasodilating Agent 18%
• Procoagulant 9%
• Pulmonary Hypertension 100%
• Thrombosis 18%
• Vascular Remodeling 9%
• Vasoconstriction 9%
• Vitamin K Antagonist 9%
• Warfarin 18%

Pharmacology, Toxicology and Pharmaceutical Science

• Anticoagulant Agent 100%
• Antivitamin K 9%
• Artery Intima Proliferation 9%
• Clinical Trial 9%
• Direct Oral Anticoagulant 18%
• Disease 36%
• Inflammation 9%
• Observational Study 9%
• Overall Survival 9%
• Peripheral Vasodilating Agent 18%
• Procoagulant 9%
• Pulmonary Hypertension 100%
• Thrombosis 18%
• Vascular Remodeling 9%
• Warfarin 18%